Home
|
Job-opportunities
|
Contact
|
News
|
Donate
Overview
DNDi Worldwide
Business Model
Stakeholders
Friends of DNDi
Our People
Annual Report
DNDi's Policies
Endorsements
Letter from Chairman and Executive Director
Diseases
Portfolio
R&D Organisation
Building Portfolio
Clinical Trial Protocols
Open Innovation
ASAQ
ASMQ
NECT
SSG&PM
Paediatric Benznidazole
LEAP Platform
HAT Platform
Chagas Platform
Technology transfer ASMQ
Technology transfer ASAQ
Global
Access
IP
Regulatory
Sustainable Funding
Press Kit
Press Releases
Press Articles
Scientific Publications
Newsletters
Outlooks
Multimedia
Events
Press Room
Business Model
Partners
IP & Licensing Policies
To Become a DNDi Partner
How to help
Donors
Key Financial Figures
Fundraising Policy
Donate
Home
Project Portfolio
R&D Phases
Diseases
Project Portfolio
Screening
Consolidated Lead Optimization
Nitroimidazole backup
Oxaborole
VL-2098
Alt. formulations Amphotericin B
Nitroimidazole
Fenarimol series
K777
Flubendazole Macrofilaricide (Helminth)
Improved PI for 1st-line
Fexinidazole
Oxaborole SCYX-7158
New VL treatments (Bangladesh)
New VL treatments (Africa)
New VL treatments (Latin America)
HIV/VL
Azoles E1224 & Biomarker (Chagas)
ASAQ
ASMQ
NECT
New VL treatments SSG/PM
New VL treatments (Asia)
Benznidazole Paedriatric dosage form
R&D Phases
R&D Organisation
Building Portfolio
Clinical Trial Protocols
Open Innovation
R&D Phases
Click here to download DNDi’s Pipeline
SITEMAP
DISCLAIMER
PRIVACY
Except where otherwise noted, content on this site is licensed under
a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License